2 recruiting, 1 completed. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Completed 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow MCI: new trials by email Literature Review of MCI trials Research Report on MCI
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FACE Phase II (a Stage II Trial) Cognitive Remediation, Cognitive Remediation II - MCI, Subjective Cognitive Decline (SCD) | Phase 1 / Phase 2 | Recruiting | Stanford University | 80 | 2025-10-31 | 2026-04-24 |
| Efficacy and Safety of Dimethyl Fumarate Among Patients with Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease dimethyl fumarate - MCI, MCI-AD, Early Stage Alzheimer's Disease | Phase 2 | Recruiting | Medical University of Lodz | 30 | 2024-10-28 | 2025-02-27 |
| Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease Methylene Blue, FD&C Blue # 2, Phenazopyridine hydrochloride - Mild Cognitive Impairment, MCI | Phase 2 | Completed | The University of Texas Health Science Center at San Antonio | 117 | 2015-07-01 | 2024-09-19 |
Alzheimer Disease (2) · Cognitive Dysfunction (1)
Brain Diseases (2) · Central Nervous System Diseases (2) · Dementia (2) · Mental Disorders (2) · Nervous System Diseases (2) · Neurocognitive Disorders (2) · Neurodegenerative Diseases (2) · Tauopathies (2) · Cognition Disorders (1)
Cognitive Remediation (1) · Dimethyl Fumarate (1) · Indigo Carmine (1) · Methylene Blue (1) · Phenazopyridine (1)
Medical University of Lodz (1) · Stanford University (1) · The University of Texas Health Science Center at San Antonio (1)
United States (2) · Poland (1)